CClinicalTrials.gg
Sign In
Not yet recruitingNCT07657247Updated Jun 18, 2026

Clinical Evaluation of the Efficacy of a Nasal Spray in the Treatment of Nasal Dryness

An interventional study of Spray pompe nasal in Nasal Dryness, sponsored by YSLab. Not yet recruiting. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by YSLab · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Study summary

The purpose of this study is to see whether the nasal spray can help improve hydration of the nasal mucosa, reduce discomfort linked to nasal dryness, and confirm its safety in patients suffering from nasal dryness.

02

Conditions studied

  • Nasal Dryness
03

In context

Lead sponsor

YSLab is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Gender: female and/or male.
  • Age: adults and children from 6 years old:
  • The physician's score for at least two symptoms, in addition to a dry nose, must average at least 2 at the enrolment visit (Day 0), for a minimum total score of 6.
  • Subjects agree to refrain from taking any medication and/or taking any action to relieve nasal symptoms throughout the study, from Day -4 to Day 7, apart from acetaminophen.
  • Autonomous adult, or minor with the consent of their legal representative.
  • Subject and/or Parent/legal guardian of the subject has given freely and expressly her/his informed consent.
  • Subject and/or Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected.
  • Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use.
  • Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.

Exclusion criteria

Exclusion Criteria:

  • Subjects taking anticoagulants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), or topical or systemic decongestants within two weeks prior to Visit 1 and during the study.
  • Subjects using other nasal sprays, nasal pumps, nasal irrigation/rinsing devices, or oils, creams, or gels in the nose within two weeks prior to Visit 1 and during the study.
  • Subjects with a history of sensitivity to products related to the product being evaluated.
  • Subjects with any clinically significant comorbid condition that, in the opinion of the principal investigator, could affect the subject's safety and/or participation in the study.
  • Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.
  • Person refusing to sign the informed consent form prior to the study.
  • Person participating or having participated in any other clinical study within the 30 days preceding the study.
  • Person participating in any other clinical study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Nasal spray

    Device: Spray pompe nasal

Interventions

  • DeviceSpray pompe nasal

    Dosage: 2 sprays per nostril

06

What researchers measure

Primary outcomes

  1. Improvement of the nasal dryness symptoms

    The changes between the baseline and day 7 will be assessed using the Rhinitis Sicca Symptom Score (RSSS). The RSSS is constituted by the sum of the following individual symptoms: sensation of dry nose, impairment of nasal breathing/nasal obstruction, crusting, itching/sneezing attacks, pain in the nose, anterior nasal discharge /runny nose, thick nasal discharge, desire to clear one's throat/ dry throat, impairment of smell and impairment of sleep. Patients assessed with each of these symptoms on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).

    Time frame: Day 0 - Day 0 immediately after first use - Day 7

Secondary outcomes

  1. Improvement of the total perceive Nasal symptom relief

    The changes between the baseline and day 7 in the rhinoscopy score will be assessed. The rhinoscopy score is constituted by the sum of the following symptom: dryness, atrophy, redness, oedema of the nasal mucosa and crusting. The clinician will assess each symptom on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).

    Time frame: Day 0 - Day 0 immediately after first use - Day 7

  2. Incidence of Adverse Events

    Adverse events, if any, will be tabulated by the investigator

    Time frame: through study completion, an average of 7 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07657247
Lead sponsor
YSLab
Collaborators
Eurofins
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

YSLab

Start the discussion